A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

被引：0
作者：
Matthew Gumbleton
Stephanie Allan
Hannah Conway
Kenneth Boucher
James Marvin
Josiah Hawks
William Burnett
Matthew Van Brocklin
Jonathan Whisenant
Glynn Gilcrease
Sumati Gupta
机构：
[1] University of Utah,Huntsman Cancer Institute
[2] University of Utah School of Medicine,Division of Oncology, Department of Internal Medicine
[3] University of Utah School of Medicine,Division of Epidemiology and Huntsman Cancer Institute, Department of Internal Medicine
[4] University of Utah,Flow Cytometry Core Facility, Health Science Center
[5] University of Utah School of Medicine,Department of Oncological Sciences
[6] University of Utah School of Medicine,Division of Oncology, Department of Surgery
[7] Department of Veterans Affairs Medical Center,undefined
来源：
BMC Research Notes | / 16卷
关键词：
APPEASE; Apatinib; Rivoceranib; Pembrolizumab; Immunotherapy; VEGF inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 132 条
[61]  
Manne S(undefined)undefined undefined undefined undefined-undefined
[62]  
Ngiow SF(undefined)undefined undefined undefined undefined-undefined
[63]  
Patel KP(undefined)undefined undefined undefined undefined-undefined
[64]  
Kim CG(undefined)undefined undefined undefined undefined-undefined
[65]  
Jang M(undefined)undefined undefined undefined undefined-undefined
[66]  
Kim Y(undefined)undefined undefined undefined undefined-undefined
[67]  
Leem G(undefined)undefined undefined undefined undefined-undefined
[68]  
Kim KH(undefined)undefined undefined undefined undefined-undefined
[69]  
Lee H(undefined)undefined undefined undefined undefined-undefined
[70]  
Hack SP(undefined)undefined undefined undefined undefined-undefined
234567891011